After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

Eli Lilly and Company Maintains Momentum in Pharmaceutical Sector Amid NYSE Healthcare Stocks Movement ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Lilly’s recently-launched direct-to-consumer campaign also embraces a digital-first approach to reach eczema patients.

On the heels of similar investment pledges from Eli Lilly and Johnson & Johnson, Switzerland’s Novartis is stepping up to the ...

As the women’s NCAA March Madness tournament draws to a close, Eli Lilly is aiming for a slam dunk of its own. | As the women ...

Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July ...

Advertisement Article continues below this ad The agency’s Committee for Medicinal Products ... patients should get the drugs and how long they might benefit. Shares of Eli Lilly and Co. climbed more ...

Hyderabad: IT and Industries D Sridhar Babu on Tuesday announced that the State government aims to make 200 million square feet of grade-A commercial space available in Hyderabad by 2030.

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...